Article Text

Download PDFPDF

Prognostic factors related to dendritic cell vaccines on patients with advanced non-small cell lung cancers: a multicenter analysis
  1. Hidenori Takahashi1,
  2. Shigetaka Shimodaira2,
  3. Masahiro Ogasawara3,
  4. Masanori Kobayashi4,
  5. Hirofumi Abe5,
  6. Kazuhiro Nagai6,
  7. Sunichi Tsujitani7,
  8. Masato Okamoto8,
  9. Yuji Morita9 and
  10. Yoshikazu Yonemitsu10
  1. Aff1 Seren Clinic Fukuoka Fukuoka Japan
  2. Aff2 grid.412568.c0000000404479995Cell Processing CenterShinshu University Hospital Matsumoto Nagano Japan
  3. Aff3 grid.415262.60000 0004 0642 244XDepartment of HematologySapporo Hokuyu Hospital Sapporo Hokkaido Japan
  4. Aff4 Seren Clinic Nagoya Nagoya Aichi Japan
  5. Aff5 Seren Clinic Kobe Kobe Hyogo Japan
  6. Aff6 grid.411873.80000000406161585Transfusion and Cell Therapy UnitNagasaki University Hospital Nagasaki Japan
  7. Aff7 grid.412799.00000000406190992Cancer CenterTottori University Hospital Yonago Tottori Japan
  8. Aff8 grid.410786.c0000000092062938Department of Advanced ImmunotherapeuticsKitasato University School of Pharmacy Tokyo Japan
  9. Aff9 Seren Clinic Tokyo Tokyo Japan
  10. Aff10 grid.177174.30000000122424849R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical SciencesKyushu University Fukuoka Japan

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Dendritic cell (DC)-based cancer vaccines may have a significant benefit to patients with advanced non-small cell lung cancers (NSCLCs). However, variations among clinical studies make it difficult to compare clinical outcomes. J-SICT DC vaccine study group is composed of the multi-medical centers in Japan, has provided DC vaccines as a compassionate use under the unified regimens for cell production and patient treatment, and published a number of clinical data of patients treated with DC vaccines. A single medical institution of this group has recently published a potentially beneficial effect of DC vaccines on overall survival of 62 patients with advanced NSCLCs[1]. Here we extended the findings to 260 patients with advanced NSCLCs who treated among 6 centers of this group.


Of 337 patients who met the inclusion criteria, 260 patients who received by weekly more than 5-times of peptide-pulsed DC vaccines were analyzed.


No serious adverse event related to DC vaccination. The mean survival time from diagnosis was 33.0 months (95%CI=27.9–39.2, 85.5% in 1-year and 66.4% in 2-years), and that from the first vaccination was 13.8 months (95%CI=11.4–16.8, 53.5% in 1-year and 36.1% in 2-years). Similar to our previous findings obtained in the analysis for advanced pancreatic cancer[2], 30 mm and more in diameter of erythema reaction at the injected site was identified as the strongest factor correlating to the overall survival from 1st vaccine (> 30 mm: MST=20.4 months, n=135 and < 30 mm: MST=8.8 months, n=122, p < 0.0001) in uni- and multivariate analyses. Importantly, the size of erythema reaction was significantly correlated with ECOG-PS, neutrophil/lymphocyte (N/L) ratio, hemoglobin, C-reactive protein, and fever (over 38 oC) at the time of leukapheresis, suggesting that the good physical condition as well as less inflammatory reaction might be important to induce stronger reaction against DC vaccines.


This is the first report of a multicenter clinical study suggesting the feasibility and possible clinical benefit of DC vaccines in patients with advanced NSCLCs. These findings suggest the potential responders against DC vaccines, and need to be addressed in well-controlled prospective randomized trials.


  1. 1.
  2. 2.